dalteparin has been researched along with Puerperal Disorders in 21 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Puerperal Disorders: Disorders or diseases associated with PUERPERIUM, the six-to-eight-week period immediately after PARTURITION in humans.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Dysfibrinogenemia is caused by a variety of structural abnormalities in the fibrinogen molecule, which results in a tendency for bleeding and thrombosis as well as obstetric complications." | 7.75 | Treatment of patients with dysfibrinogenemia and a history of abortions during pregnancy. ( Galanakis, D; Miesbach, W; Scharrer, I, 2009) |
| " In a randomised open study, 44 pregnant women with confirmed previous or current thromboembolism were randomised to receive either low-molecular-weight heparin, dalteparin (N = 21) once daily subcutaneously or unfractionated sodium heparin (UF heparin, N = 23) twice daily subcutaneously for thromboprophylaxis during pregnancy and puerperium." | 5.10 | Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. ( Hiilesmaa, V; Kaaja, R; Leinonen, P; Markkola, A; Pettilä, V, 2002) |
| "Dysfibrinogenemia is caused by a variety of structural abnormalities in the fibrinogen molecule, which results in a tendency for bleeding and thrombosis as well as obstetric complications." | 3.75 | Treatment of patients with dysfibrinogenemia and a history of abortions during pregnancy. ( Galanakis, D; Miesbach, W; Scharrer, I, 2009) |
| "Coronavirus is a source of deep venous thrombosis (DVT) due to complications such as over-coagulation, blood stasis, and endothelial damage." | 1.62 | Ovarian vein thrombosis after coronavirus disease (COVID-19) mimicking acute abdomen: two case reports. ( Abdeladim, S; Bensahi, I; Elouarradi, A; Fatimazahra, M; Harras, ME; Kassimi, M; Oualim, S; Sabry, M, 2021) |
| "These findings suggest that vertebral compression fractures and PPO may be one of the causes of severe back pain in postpartum patients." | 1.42 | Postpartum osteoporosis and vertebral fractures in two patients treated with enoxaparin during pregnancy. ( Cakir, B; Dirikoc, A; Ersoy, R; Ozdemir, D; Tam, AA, 2015) |
| "Among patients with cancer-related VTE, 59." | 1.38 | Management and adherence to VTE treatment guidelines in a national prospective cohort study in the Canadian outpatient setting. The Recovery Study. ( Blostein, M; Faucher, JP; Gamble, G; Game, M; Gordon, W; Kagoma, PK; Kahn, SR; Komari, N; Laverdière, D; Martineau, J; McLeod, A; Mills, A; Miron, MJ; Schulman, S; Springmann, V; Stewart, JA; Strulovitch, C, 2012) |
| "Nadroparin is both safe and effective for the treatment of DVT during pregnancy and puerperium." | 1.36 | Efficacy and safety of nadroparin and unfractionated heparin for the treatment of venous thromboembolism during pregnancy and puerperium. ( Antonijević, N; Djordjević, V; Ilić, V; Kovac, M; Lazić, R; Mitić, G; Novakov-Mikić, A; Povazan, L; Salatić, I, 2010) |
| "Given that deep vein thrombosis coincided with obstetric delivery, it was crucial to decide on anesthetic and therapeutic approaches that would assure maternal and fetal safety and prevent such complications as massive pulmonary thromboembolism." | 1.36 | [Parturient at full term with inferior vena cava thrombosis: anesthesia during surgical delivery]. ( Amorós, B; Bermejo, L; Dueñas, N; Fernández, E; Perea, M; Villafranca, A, 2010) |
| "Gastrointestinal stromal tumors are the commonest stromal tumors of the digestive tract." | 1.36 | [Gastrointestinal stromal tumor in pregnancy and control. Case report]. ( Cuerva-González, MJ; de la Calle-Fernández, M; Lacoponi, S; Pozo-Krielinger, J, 2010) |
| "Discontinuing LMWH more than 12 hours before delivery is safe in relation to maternal hemorrhagic complications." | 1.33 | The safety of low molecular weight heparin therapy during labor. ( Kupferminc, MJ; Landsberg, JA; Lessing, JB; Many, A; Maslovitz, S; Varon, D, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (9.52) | 18.2507 |
| 2000's | 7 (33.33) | 29.6817 |
| 2010's | 11 (52.38) | 24.3611 |
| 2020's | 1 (4.76) | 2.80 |
| Authors | Studies |
|---|---|
| Mitić, G | 1 |
| Kovac, M | 1 |
| Povazan, L | 1 |
| Djordjević, V | 1 |
| Ilić, V | 1 |
| Salatić, I | 1 |
| Lazić, R | 1 |
| Antonijević, N | 1 |
| Novakov-Mikić, A | 1 |
| Fatimazahra, M | 1 |
| Harras, ME | 1 |
| Bensahi, I | 1 |
| Kassimi, M | 1 |
| Oualim, S | 1 |
| Elouarradi, A | 1 |
| Abdeladim, S | 1 |
| Sabry, M | 1 |
| Robison, E | 1 |
| Heyborne, K | 1 |
| Allshouse, AA | 1 |
| Valdez, C | 1 |
| Metz, TD | 1 |
| Moriuchi, K | 1 |
| Chigusa, Y | 1 |
| Kondoh, E | 1 |
| Murakami, R | 1 |
| Ueda, Y | 1 |
| Mogami, H | 1 |
| Mandai, M | 1 |
| Lucania, G | 1 |
| Camiolo, E | 1 |
| Carmina, MG | 1 |
| Fiandaca, T | 1 |
| Indovina, A | 1 |
| Malato, A | 1 |
| Messina, R | 1 |
| Fabbiano, F | 1 |
| Marcenò, R | 1 |
| Ozdemir, D | 1 |
| Tam, AA | 1 |
| Dirikoc, A | 1 |
| Ersoy, R | 1 |
| Cakir, B | 1 |
| Miesbach, W | 1 |
| Galanakis, D | 1 |
| Scharrer, I | 1 |
| Salomon, O | 1 |
| Dulitzky, M | 1 |
| Apter, S | 1 |
| Fernández, E | 1 |
| Dueñas, N | 1 |
| Villafranca, A | 1 |
| Perea, M | 1 |
| Amorós, B | 1 |
| Bermejo, L | 1 |
| Ferres, MA | 1 |
| Olivarez, SA | 1 |
| Trinh, V | 1 |
| Davidson, C | 1 |
| Sangi-Haghpeykar, H | 1 |
| Aagaard-Tillery, KM | 1 |
| Cuerva-González, MJ | 1 |
| Lacoponi, S | 1 |
| de la Calle-Fernández, M | 1 |
| Pozo-Krielinger, J | 1 |
| Kahn, SR | 1 |
| Springmann, V | 1 |
| Schulman, S | 1 |
| Martineau, J | 1 |
| Stewart, JA | 1 |
| Komari, N | 1 |
| McLeod, A | 1 |
| Strulovitch, C | 1 |
| Blostein, M | 1 |
| Faucher, JP | 1 |
| Gamble, G | 1 |
| Gordon, W | 1 |
| Kagoma, PK | 1 |
| Miron, MJ | 1 |
| Laverdière, D | 1 |
| Game, M | 1 |
| Mills, A | 1 |
| Maslovitz, S | 1 |
| Many, A | 1 |
| Landsberg, JA | 1 |
| Varon, D | 1 |
| Lessing, JB | 1 |
| Kupferminc, MJ | 1 |
| Santoro, R | 1 |
| Iannaccaro, P | 1 |
| Sottilotta, G | 1 |
| Kenny, B | 1 |
| Volobuev, V | 1 |
| Gibson, JL | 1 |
| Ekevall, K | 1 |
| Walker, I | 1 |
| Greer, IA | 1 |
| Lindqvist, PG | 1 |
| Dahlbäck, B | 1 |
| Ellison, J | 1 |
| Thomson, AJ | 1 |
| Conkie, JA | 1 |
| McCall, F | 1 |
| Walker, D | 1 |
| Greer, A | 1 |
| Herzog, S | 1 |
| Rath, W | 1 |
| Kuhn, W | 1 |
| Pettilä, V | 1 |
| Leinonen, P | 1 |
| Markkola, A | 1 |
| Hiilesmaa, V | 1 |
| Kaaja, R | 1 |
| Østergaard, S | 1 |
| Hvas, AM | 1 |
| Medrud, L | 1 |
| Fuglsang, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of UFH and LMWH on Osteoprotegerin and RANKL Plasma Levels in Hemodialysis Patients[NCT00669721] | 40 participants (Anticipated) | Interventional | 2008-03-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for dalteparin and Puerperal Disorders
| Article | Year |
|---|---|
Puerperal thromboprophylaxis: comparison of the anti-Xa activity of enoxaparin and unfractionated heparin.
Topics: Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Female; Heparin; Heparin, Low-Molecular-Weight; Hu | 1998 |
Thromboprophylaxis following caesarean section--a comparison of the antithrombotic properties of three low molecular weight heparins--dalteparin, enoxaparin and tinzaparin.
Topics: Adolescent; Adult; Anticoagulants; Antithrombin III; Cesarean Section; Dalteparin; Enoxaparin; Facto | 2001 |
Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin.
Topics: Absorptiometry, Photon; Adult; Anticoagulants; Bone Density; Dalteparin; Factor Xa Inhibitors; Femal | 2002 |
18 other studies available for dalteparin and Puerperal Disorders
| Article | Year |
|---|---|
Efficacy and safety of nadroparin and unfractionated heparin for the treatment of venous thromboembolism during pregnancy and puerperium.
Topics: Anticoagulants; Female; Fibrinolytic Agents; Heparin; Humans; Nadroparin; Pregnancy; Pregnancy Compl | 2010 |
Ovarian vein thrombosis after coronavirus disease (COVID-19) mimicking acute abdomen: two case reports.
Topics: Abdomen, Acute; Adult; Anticoagulants; COVID-19; Diagnosis, Differential; Enoxaparin; Female; Fibrin | 2021 |
Implementation of a Risk-Based Heparin Protocol for Postpartum Venous Thromboembolism Prevention.
Topics: Adolescent; Adult; Anticoagulants; Cohort Studies; Enoxaparin; Female; Humans; Puerperal Disorders; | 2017 |
Enoxaparin administration within 24 hours of caesarean section: a 6-year single-centre experience and patient outcomes.
Topics: Adult; Anticoagulants; Cesarean Section; Enoxaparin; Female; Humans; Pregnancy; Pregnancy Complicati | 2019 |
Multidisciplinary approach in pregnancy-associated thrombotic thrombocytopenic purpura: a case report.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Anticoagulants; Cesarean Section; Combined Modality T | 2014 |
Postpartum osteoporosis and vertebral fractures in two patients treated with enoxaparin during pregnancy.
Topics: Absorptiometry, Photon; Adult; Anticoagulants; Bone Density; Enoxaparin; Female; Fractures, Compress | 2015 |
Treatment of patients with dysfibrinogenemia and a history of abortions during pregnancy.
Topics: Abortion, Habitual; Abruptio Placentae; Adult; Afibrinogenemia; Enoxaparin; Female; Fibrinogen; Fibr | 2009 |
New observations in postpartum ovarian vein thrombosis: experience of single center.
Topics: Adult; Anticoagulants; Aspirin; Cesarean Section; Early Diagnosis; Enoxaparin; Female; Humans; Incid | 2010 |
[Parturient at full term with inferior vena cava thrombosis: anesthesia during surgical delivery].
Topics: Adult; Anesthesia, General; Anesthesia, Obstetrical; Anticoagulants; Cesarean Section; Emergencies; | 2010 |
Rate of wound complications with enoxaparin use among women at high risk for postpartum thrombosis.
Topics: Adult; Anticoagulants; Cesarean Section; Enoxaparin; Female; Humans; Puerperal Disorders; Retrospect | 2011 |
[Gastrointestinal stromal tumor in pregnancy and control. Case report].
Topics: Adult; Anticoagulants; Cesarean Section; Embolism, Amniotic Fluid; Emergencies; Enoxaparin; Female; | 2010 |
Management and adherence to VTE treatment guidelines in a national prospective cohort study in the Canadian outpatient setting. The Recovery Study.
Topics: Adult; Aged; Anticoagulants; Canada; Catheterization; Coumarins; Disease Management; Drug Utilizatio | 2012 |
The safety of low molecular weight heparin therapy during labor.
Topics: Adult; Anticoagulants; Drug Administration Schedule; Enoxaparin; Female; Hemoglobins; Hemorrhage; He | 2005 |
Congenital hypodysfibrinogenemia and abruptio placentae in a woman with history of cerebral thrombosis.
Topics: Abruptio Placentae; Adult; Anticoagulants; Enoxaparin; Female; Fibrinogens, Abnormal; Heparin; Human | 2007 |
Splenic rupture following elective caesarean delivery at term, complicated by low-molecular-weight heparin use.
Topics: Abdominal Pain; Adult; Anticoagulants; Antithrombin III Deficiency; Cesarean Section; Comorbidity; E | 2007 |
Bleeding complications associated with low molecular weight heparin prophylaxis during pregnancy.
Topics: Anemia; Anticoagulants; Dalteparin; Delivery, Obstetric; Dextrans; Enoxaparin; Female; Hemorrhage; H | 2000 |
[Successful therapy of heparin-associated thrombocytopenia with a low sulfated heparinoid].
Topics: Adult; Anticoagulants; Cesarean Section; Chondroitin Sulfates; Cross Reactions; Dalteparin; Dermatan | 1995 |
Ovarian vein thrombosis after delivery.
Topics: Adult; Cesarean Section; Delivery, Obstetric; Diagnosis, Differential; Female; Follow-Up Studies; He | 2018 |